HLA-DR genotypes in patients with systemic lupus erythematosus in Taiwan.
Journal
Journal of the Chinese Medical Association : JCMA
ISSN: 1728-7731
Titre abrégé: J Chin Med Assoc
Pays: Netherlands
ID NLM: 101174817
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
7
12
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
Different human leukocyte antigen (HLA)-DR genotypes have been known to be associated with the risk of development of systemic lupus erythematosus (SLE) in different populations, although Lu et al. have reported previously that no correlation exists between the HLA-DR genotype and disease manifestation in SLE patients in Taiwan. We investigated the effects different HLA-DR genotypes had on SLE incidence in Taiwanese patients as to whether risk alleles were associated with different clinical manifestations, and the effects risk alleles had on the age of disease onset. Two hundred thirty-four SLE patients and 346 healthy controls were enrolled. HLA-DR genotyping was performed with the HLA FluoGene DRDQ kit for each subject. Chi-square tests and t tests were performed for statistical analysis. HLA-DR2 was significantly more frequently found in SLE patients than in controls (odds ratio [OR] = 2.05, 95% CI, 1.44-2.92, p < 0.001). Notably, HLA-DR6 appeared to trend toward negative correlation with SLE, whereas HLA-DR8 appeared to trend toward positive correlation. HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis). HLA-DR2 was associated with SLE susceptibility in this Taiwanese population as well as lower age of disease onset and more severe clinical manifestations.
Sections du résumé
BACKGROUND
Different human leukocyte antigen (HLA)-DR genotypes have been known to be associated with the risk of development of systemic lupus erythematosus (SLE) in different populations, although Lu et al. have reported previously that no correlation exists between the HLA-DR genotype and disease manifestation in SLE patients in Taiwan. We investigated the effects different HLA-DR genotypes had on SLE incidence in Taiwanese patients as to whether risk alleles were associated with different clinical manifestations, and the effects risk alleles had on the age of disease onset.
METHODS
Two hundred thirty-four SLE patients and 346 healthy controls were enrolled. HLA-DR genotyping was performed with the HLA FluoGene DRDQ kit for each subject. Chi-square tests and t tests were performed for statistical analysis.
RESULTS
HLA-DR2 was significantly more frequently found in SLE patients than in controls (odds ratio [OR] = 2.05, 95% CI, 1.44-2.92, p < 0.001). Notably, HLA-DR6 appeared to trend toward negative correlation with SLE, whereas HLA-DR8 appeared to trend toward positive correlation. HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis).
CONCLUSION
HLA-DR2 was associated with SLE susceptibility in this Taiwanese population as well as lower age of disease onset and more severe clinical manifestations.
Identifiants
pubmed: 37801591
doi: 10.1097/JCMA.0000000000001009
pii: 02118582-990000000-00285
doi:
Substances chimiques
HLA-DR2 Antigen
0
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1060-1065Informations de copyright
Copyright © 2023, the Chinese Medical Association.
Déclaration de conflit d'intérêts
Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
Références
Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol. 2007;19:49–54.
Cooper GS, Gilbert KM, Greidinger EL, James JA, Pfau JC, Reinlib L, et al. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Environ Health Perspect. 2008;116:695–702.
Mak A, Tay SH. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci. 2014;15:16043–56.
Kamen DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin North Am. 2014;40:401–12, vii.
Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML, et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci USA. 1998;95:14875–9.
Gaffney PM, Ortmann WA, Selby SA, Shark KB, Ockenden TC, Rohlf KE, et al. Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families. Am J Hum Genet. 2000;66:547–56.
Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest. 1997;99:725–31.
Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA. 1998;95:14869–74.
Karassa FB, Trikalinos TA, Ioannidis JPA; FcgammaRIIa-SLE Meta-Analysis Investigators. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002;46:1563–71.
Grumet FC, Coukell A, Bodmer JG, Bodmer WF, McDevitt HO. Histocompatibility (HL-A) antigens associated with systemic lupus erythematosus: a possible genetic predisposition to disease. N Engl J Med. 1971;285:193–6.
Fernando MMA, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;4:e1000024.
Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum. 1998;41:1161–72.
Galeazzi M, Sebastiani GD, Morozzi G, Carcassi C, Ferrara GB, Scorza R, et al.; European Concertee Action on the Immunogenetics of SLE. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltim). 2002;81:169–78.
Morris DL, Taylor KE, Fernando MMA, Nititham J, Alarcón-Riquelme ME, Barcellos LF, et al.; International MHC and Autoimmunity Genetics Network. Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am J Hum Genet. 2012;91:778–93.
Doherty DG, Ireland R, Demaine AG, Wang F, Veerapan K, Welsh KI, et al. Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus in southern Chinese. Arthritis Rheum. 1992;35:641–6.
Hashimoto H, Nishimura Y, Dong RP, Kimura A, Sasazuki T, Yamanaka K, et al. HLA antigens in Japanese patients with systemic lupus erythematosus. Scand J Rheumatol. 1994;23:191–6.
Koskenmies S. Linkage mapping of systemic lupus erythematosus (SLE) in Finnish families multiply affected by SLE. J Med Genet. 2004;41:2e–5.
Koskenmies S, Widén E, Onkamo P, Sevón P, Julkunen H, Kere J. Haplotype associations define target regions for susceptibility loci in systemic lupus erythematosus. Eur J Hum Genet. 2004;12:489–94.
Forabosco P, Gorman JD, Cleveland C, Kelly JA, Fisher SA, Ortmann WA, et al. Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus. Genes Immun. 2006;7:609–14.
Tsuchiya N, Kawasaki A, Tsao B, Komata T, Grossman J, Tokunaga K. Analysis of the association of HLA-DRB1, TNFα promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes Immun. 2001;2:317–22.
Fernando MMA, Stevens CR, Sabeti PC, Walsh EC, McWhinnie AJM, Shah A, et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet. 2007;3:e192.
Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Genome-wide pathway analysis of genome-wide association studies on systemic lupus erythematosus and rheumatoid arthritis. Mol Biol Rep. 2012;39:10627–35.
Alarcón-Riquelme ME, Ziegler JT, Molineros J, Howard TD, Moreno-Estrada A, Sánchez-Rodríguez E, et al. Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol. 2016;68:932–43.
Lu LY, Ding WZ, Fici D, Deulofeut R, Cheng HH, Cheu CC, et al. Molecular analysis of major histocompatibility complex allelic associations with systemic lupus erythematosus in Taiwan. Arthritis Rheum. 1997;40:1138–45.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151–9.
Vyas JM, Van Der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8:607–18.
Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005;4:189–94.
Schiller M, Bekeredjian-Ding I, Heyder P, Blank N, Ho AD, Lorenz HM. Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis. Cell Death Differ. 2008;15:183–91.
Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998;188:2163–73.
Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1241–50.
Maniati E, Potter P, Rogers N, Morley B. Control of apoptosis in autoimmunity. J Pathol. 2008;214:190–8.
Lee HS. Independent association of HLA-DR and FC receptor polymorphisms in Korean patients with systemic lupus erythematosus. Rheumatol. 2003;42:1501–7.
Furukawa H, Kawasaki A, Oka S, Ito I, Shimada K, Sugii S, et al. Human leukocyte antigens and systemic lupus erythematosus: a protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One. 2014;9:e87792.
Bettencourt A, Carvalho C, Leal B, Brás S, Lopes D, Martins da Silva A, et al. The protective role of HLA-DRB1 13 in autoimmune diseases. J Immunol Res. 2015;2015:1–6.
Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12:825–35.
Azizah MR, Ainoi SS, Kuak SH, Kong NC, Normaznah Y, Rahim MN. The association of the HLA class II antigens with clinical and autoantibody expression in Malaysian Chinese patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol. 2001;19:93–100.
Marchini M, Antonioli R, Lleò A, Barili M, Caronni M, Origgi L, et al. HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol. 2003;64:462–8.
Wadi W, Elhefny NEAM, Mahgoub EH, Almogren A, Hamam KD, Al-Hamed HA, et al. Relation between HLA typing and clinical presentations in systemic lupus erythematosus patients in Al-Qassim Region, Saudi Arabia. Int J Health Sci. 2014;8:159–65.
Bhallil O, Ibrahimi A, Ouadghiri S, Ouzeddoun N, Benseffaj N, Bayahia R, et al. HLA class II with lupus nephritis in Moroccan patients. Immunol Invest. 2017;46:1–9.
de Holanda MI, Klumb E, Imada A, Lima LA, Alcântara I, Gregório F, et al. The prevalence of HLA alleles in a lupus nephritis population. Transpl Immunol. 2018;47:37–43.
Gunawan A, Handono K, Kalim H, Susianti H, Eko MH, Lawrence GS, et al. The importance of HLA-DRB1 alleles in patients with lupus nephritis. Turk J Immunol. 2018;6:118–22.
Diaz-Gallo L, Oke V, Lundström E, Elvin K, Ling Wu Y, Eketjäll S, et al. Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA-DRB1 genotype associations and immunological and clinical manifestations. ACR Open Rheumatol. 2022;4:27–39.
Bastian HM, Alarcon GS, Roseman JM, McGwin G, Vila LM, Fessler BJ, et al.; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatol. 2006;46:683–9.
Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, et al.; International Consortium for Systemic Lupus Erythematosus Genetics. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol. 2014;25:2859–70.
Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis. 2015;18:17–28.
Morimoto S, Hashimoto H, Yamanaka K, Tokano Y, Nishimura Y, Sawada S, et al. Multicenter cooperative study of HLA class II alleles in Japanese patients with systemic lupus erythematosus. Mod Rheumatol. 2000;10:235–9.
Chang C, Greenspan A, Gershwin ME. Osteonecrosis. In: Firestein GS, editor. Firestein & Kelley’s textbook of rheumatology. 11th ed. Elsevier; 2021, p. 1852–3.
Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis. 2000;59:462–7.
Prasad R, Ibanez D, Gladman D, Urowitz M. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16:157–62.
Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, et al. Procoagulants and osteonecrosis. J Rheumatol. 2003;30:783–91.
Smikle M, Christian N, DeCeulaer K, Barton E, Roye-Green K, Dowe G, et al. HLA-DRB alleles and systemic lupus erythematosus in Jamaicans. South Med J. 2002;95:717–9.
Selvaraja M, Chin VK, Abdullah M, Arip M, Amin-Nordin S. HLA-DRB1*04 as a risk allele to systemic lupus erythematosus and lupus nephritis in the Malay population of Malaysia. Front Med. 2021;7:598665.
Bang SY, Choi JY, Park S, Choi J, Hong SJ, Lee HS, et al. Influence of susceptibility HLA-DRB1 alleles on the clinical subphenotypes of systemic lupus erythematosus in Koreans: HLA-DRB1 associated with SLE. Arthritis Rheumatol. 2016;68:1190–6.
Bell DA, Rigby R, Stiller CR, Clark WF, Harth M, Ebers G. HLA antigens in systemic lupus erythematosus: relationship to disease severity, age at onset, and sex. J Rheumatol. 1984;11:475–9.
Davies EJ, Hillarby MC, Cooper RG, Hay EM, Green JR, Shah S, et al. HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol. 1993;32:870–5.
Webb R, Kelly JA, Somers EC, Hughes T, Kaufman KM, Sanchez E, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis. 2011;70:151–6.
Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. 2012;2012:1–7.
Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18:575–90.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–21.
Stickler M, Valdes AM, Gebel W, Razo OJ, Faravashi N, Chin R, et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4+ T-cell epitope in human interferon-β. Genes Immun. 2004;5:1–7.
Mangalam AK, Taneja V, David CS. HLA Class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J Immunol. 2013;190:513–8.
Rudwaleit M, Gibson K, Wordsworth P, Pile K, Oh V. HLA associations of systemic lupus erythematosus in Chinese from Singapore. Ann Rheum Dis. 1995;54:686–7.